Pfizer has revised its profit forecast for 2026 downwards, reflecting ongoing challenges from the Covid-19 pandemic and impending patent expirations on key products. The pharmaceutical giant is grappling with a significant decline in demand for its Covid vaccines and treatments, which have been pivotal to its revenue streams over the past few years. As these products face market saturation and competition, Pfizer’s financial outlook has understandably dimmed.
In response to these pressures, Pfizer is not only implementing a robust $7.7 billion cost-cutting strategy but is also strategically investing in its cardiometabolic pipeline. This dual approach aims to bolster its portfolio as it seeks to penetrate the lucrative obesity market, which is projected to grow significantly in the coming years. By pivoting towards this area, Pfizer hopes to mitigate the impact of its current challenges and position itself for future growth.
Use the database as your supply chain compass →
